Intravitreal bevacizumab for choroidal neovascularization secondary to inflammation.
Armin
A
Wolf
Stephan
S
Thurau
Daniel
D
Kook
Anna
A
Hoeing
Siegfried
S
Priglinger
Anselm
A
Kampik
Christos
C
Haritoglou
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002825:Chorioretinitis / Q000150:complications*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D056965:Injections, Intraocular; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab